Glaukos delivered consolidated net sales of $150.6 million in Q1 2026, a 41% increase year-on-year on a reported basis and 39% on a constant currency basis. iDose TR contributed approximately $54 million in sales, reflecting broad-based adoption across established and newer Medicare Administrative Contractors.

iDose TR’s strong clinical outcomes and payer coverage expansion into commercial and Medicare Advantage segments drove significant physician interest. Epioxa, the company’s novel corneal cross-linking therapy, launched commercially with positive initial surgeon feedback and established pathways covering over 100 million US commercial lives.

Glaukos raised its full-year 2026 net sales outlook to $620–$635 million, up from $600–$620 million previously. Management projects US glaucoma sales to grow in the low 30% range, international glaucoma and corneal health franchises to achieve high single-digit growth.

Despite encouraging early claims and procedures for Epioxa, reimbursement challenges persist in certain regions such as CGS and WPS, potentially affecting near-term adoption. Ongoing Phase 4 studies for iDose aim to bolster payer engagement by demonstrating incremental value alongside cataract surgery.